期刊文献+

依巴斯汀联合多塞平治疗慢性荨麻疹的临床观察 被引量:4

Clinical observation on efficacy of ebastine combined with doxepin and ebastine alone in treatment of chronic urticaria patients
原文传递
导出
摘要 目的评价依巴斯汀联合多塞平治疗慢性荨麻疹的疗效。方法采用随机开放平行对照的方法将100例慢性荨麻疹患者随机分成依巴斯汀、多塞平联合治疗组和单纯依巴斯汀治疗组,分别予依巴斯汀10mg联合多塞平25mg和单纯依巴斯汀治疗,均每日1次口服,观察第28d的疗效及停药1周后的复发率。结果治疗28d后两组有效率分别为96%、74%,两组差异具有显著性(χ2=3.45,P<0.05)。停药1周后的复发率,治疗组为24%,显著低于对照组的46%(χ2=4.32,P<0.05)。结论依巴斯汀联合多塞平治疗慢性特发性荨麻疹疗效高,复发率低,值得临床推广。 Objective To evaluate the efficacy of ebastine combined with doxepin in treatment of chronic urticaria.Methods A randomized clinical trial on 100 patients was conducted.The patients were divided randomly into ebastine combined with doxepin group(study group)and ebastine group(control group),The patients in study group were treated with daily ebasdine 10mg combined with doxepin 25mg and those in the control group were treated with ebasdine 10mg alone.The recurrent rates were also recorded 4 weeks after discontinuation of the treatment.Results The effective rate of study group and control group were 96.0% and 75% respectively without showing significant difference between the two groups(X=3.45,P0.05).Conclusions The efficacy of bbasdine combined with doxepin is high in treatment of chronic urticaria with low recurrent rate.
出处 《中国热带医学》 CAS 2013年第3期365-366,共2页 China Tropical Medicine
关键词 慢性荨麻疹 依巴斯订 多塞平 疗效 Chronic urticaria Ebastine Doxepin Therapeutic effevt
  • 相关文献

参考文献5

二级参考文献21

  • 1吴瑞勤,孙越,朱光斗,郑捷,徐慧珍,张定国,姜培红,郑志忠,杨勤萍.依巴斯汀治疗慢性特发性荨麻疹临床观察[J].临床皮肤科杂志,2004,33(8):507-507. 被引量:53
  • 2杭守云.咪唑斯汀治疗慢性特发性荨麻疹38例疗效观察[J].临床皮肤科杂志,2005,34(11):777-777. 被引量:8
  • 3[2]Hurst M, Spencer M. Ebastine: An update of its use in allergic disordes[J]. Drugs, 2000, 59(4): 981-1006.
  • 4[3]Kaplan AP. Clinical practice. Chronic urticaria and angioedema[J].N Engl J Med, 2002, 346(3): 175-179.
  • 5[4]Gispert J, Antonijoan R, Barbanoj M, et al. Efficacy of ebastine,cetirizine, and loratadine in histamine cutaneous challenges[J]. Ann Allergy Asthma Immunol, 2002, 89(3): 259-364.
  • 6[5]Malik M. Problems of heart rate correction in assessment of druginduced QT interval prolongation[J]. J Cardiovasc Electrophysiol,2001, 12(4): 411-420.
  • 7[6]Hindmarch I, Shamsi Z. Antihistamine: models to assess sedative properties, assessment of sedation, safety and other side-effects[J]. Clin Exp Allergy, 1999, 29(3): 133-142.
  • 8Van Cauwenberge P, De Belder T, Sys L. A review of the second-generation antihistamine ebastine for the treatment of allergic disorders. Expert Opin Pharmacother 2004,5 : 1807 - 1813.
  • 9Roberts DJ. A preclinical overview of ebastine. Studies on the pharmacological properties of a novel histamine H1 receptor antagonist.Drugs 1996,52(Suppl 1) :8 - 14.
  • 10Grant JA, Riethuisen JM, Moulaert B, et al. A double - bhnd, randomized, single - dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine - induced wheal - and - flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Imrnunol 2002,88:190- 197.

共引文献81

同被引文献25

引证文献4

二级引证文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部